Fit-for-purpose analytics for cannabis: identification, quantification, and standardization of cannabinoids,...

Cannabis-based products used in medicine and wellness are chemically complex mixtures of cannabinoids, terpenes, flavonoids (including cannflavins), and degradation products whose profiles can shift substantially with cultivar genetics, cultivation conditions, extraction workflows, formulation choices, and storage history. This field-to-field and lab-to-lab variability, compounded by inconsistent analytical practices and uneven validation standards, can undermine potency labeling, cross-product comparability, and the interpretation of clinical and pharmacological findings. This review critically summarizes current quantitative and fingerprint-based strategies for measuring cannabinoids and related constituents across major product types (flowers/biomass, oils, edibles, and vape products) and proposes a practical "field-to-result" framework spanning sampling, method selection, validation, and lifecycle quality control. Drawing on peer-reviewed literature and metrological guidance, we evaluate LC-UV/LC-MS/MS, GC-FID/GC-MS, quantitative and structural NMR, and selected spectroscopic and aerosol approaches, with emphasis on isotope-dilution concepts, calibration design, matrix effects, validation criteria, and chemometric tools for multivariate fingerprints. The evidence is synthesized to map analyte classes and matrices to fit-for-purpose platforms and sample preparation schemes, highlight best practices for internal standards and matrix-matched calibration, and summarize commonly applied acceptance expectations for accuracy and precision. Strategies to reduce or correct matrix effects are detailed, and the role of high-dimensional fingerprints is explained as a complement to targeted potency panels for identity confirmation, process drift monitoring, lot release decisions, and traceability. Overall, combining validated potency assays with statistically governed fingerprinting offers a pragmatic route to harmonize cannabinoid testing, improve data integrity, and better support future phytomedicine research, clinical translation, and regulatory oversight.